Inhibitor Deucravacitinib nyob rau hauv Kev Kho Mob ntawm Ulcerative Colitis (UC) Pov Thawj-of-concept Phase 2 Kev Kawm Ua Tsis Tau!

Bristol-Myers Squibb (BMS) tsis ntev los no tau tshaj tawm tias Phase 2 LATTICE-UC txoj kev tshawb fawb soj ntsuam cov tshuaj tiv thaiv kab mob tshiab deucravacitinib (BMS-986165) thiab cov placebo rau kev kho mob ntawm cov mob nruab nrab mus rau qhov mob hnyav heev (UC) tsis tau raws li lub ntsiab lus kawg. (12th) Kev tshem tawm txhua lub limtiam), thiab tsis tau mus txog qhov kawg ntawm qhov kev ua tau zoo thib ob. Hauv txoj kev tshawb no, kev nyab xeeb ntawm deucravacitinib tau ua raws li cov kev tshawb fawb yav dhau los qhia txog psoriasis thiab psoriatic mob caj dab, thiab tsis pom muaj kev nyab xeeb tshiab.

Lub tuam txhab yuav ua kom tiav cov kev tshuaj xyuas tag nrho ntawm LATTICE-UC cov ntaub ntawv kawm thiab yuav txuas ntxiv ntsuas lub peev xwm ntawm deucavitinib hauv kev kho mob ntawm UC hauv Phase 2 IM011-127 mus sib hais (nrog rau cov koob tshuaj ntau dua).

Deucravacitinib yog thawj-hauv-chav kawm, qhov ncauj, xaiv tyrosine kinase 2 (TYK2) inhibitor nrog cov txheej txheem tshwj xeeb ntawm inhibiting IL-12, IL-23, thiab hom 1 interferon txoj kev. Cov tshuaj no yog thawj thiab tsuas yog TYK2 inhibitor los soj ntsuam hauv kev tshawb fawb soj ntsuam rau kev kho mob ntawm ntau yam kab mob tiv thaiv kab mob.

Samit Hirawat, MD, Tus Thawj Saib Xyuas Kev Kho Mob ntawm Bristol-Myers Squibb tau hais tias:" Deucravacitinib tau raug pov thawj tias yog ib qho zoo heev, thawj-hauv-chav qhov ncauj xaiv TYK2 inhibitor rau kev kho mob psoriasis. Tam sim no peb tab tom ua qhov kev sim theem 3. Tshawb nrhiav lub peev xwm ntawm deucavitinib hauv kev kho mob psoriatic mob caj dab. Txawm hais tias peb tsis tau ua tiav cov ntaub ntawv pov thawj-ntawm-lub tswv yim hauv Phase 2 LATTICE-UC txoj kev tshawb fawb, peb tau cog lus tias yuav txhawb nqa deucavitinib hauv cov kab mob plab hnyuv (xws li UC thiab Crohn's disease [CD]) thiab cov haujlwm kho mob hauv psoriatic mob caj dab, lupus thiab lwm yam. cov kab mob tiv thaiv kab mob. Bristol-Myers Squibb ua tsaug rau cov neeg mob thiab cov kws tshawb fawb uas tau koom nrog LATTICE-UC kev sim tshuaj."

Deucravacitinib tshuaj qauv

Deucravacitinib yog ib qho kev xaiv qhov ncauj tshiab TYK2 inhibitor tsim los ntawm Bristol-Myers Squibb. Nws muaj cov txheej txheem tshwj xeeb ntawm kev ua haujlwm uas txawv ntawm lwm cov kinase inhibitors. TYK2 yog intracellular teeb liab kinase uas kho cov teeb liab hloov ntawm IL-23, IL-12, thiab hom I IFN. Cov cytokines no yog ntuj cytokines koom nrog hauv o thiab tiv thaiv kab mob.

Tam sim no, deucravacitinib tau raug soj ntsuam rau kev kho mob ntawm ntau yam kab mob tiv thaiv kab mob, suav nrog psoriasis, psoriatic mob caj dab, lupus, thiab kab mob plab hnyuv. EvaluatePharma, lub koom haum tshawb fawb kev lag luam tshuaj, tau tshaj tawm tsab ntawv tshaj tawm thaum pib ntawm lub xyoo no kwv yees tias kev muag khoom ntawm deucravacitinib hauv 2026 yuav ncav cuag 2.21 billion US dollars.

Thaum lub Plaub Hlis Ntuj xyoo no, Bristol-Myers Squibb tshaj tawm ntawm 2021 American Academy of Dermatology Virtual Conference Experience (AAD VMX) ob qhov tseem ceeb Theem 3 kev tshawb fawb (POETYK PSO-1, POETYK PSO-2) tau txais txiaj ntsig zoo.

Cov txiaj ntsig tau pom tias ob txoj kev tshawb fawb tau mus txog cov ntsiab lus tseem ceeb thiab theem nrab: nws tau lees paub tias deucravacitinib (6 mg, ib hnub ib zaug) muaj txiaj ntsig zoo thiab zoo dua piv nrog cov placebo thiab Otezla (apremilast, 30 mg, ob zaug ib hnub), suav nrog Qhov feem pua ​​​​siab dua ntawm cov neeg mob psoriasis cheeb tsam thiab qhov ntsuas qhov hnyav tsawg kawg yog 75% kev txhim kho los ntawm lub hauv paus (PASI75) piv nrog cov placebo thiab Otezla ntawm lub lim tiam 16, tus kws kho mob zoo li kev ntsuam xyuas tag nrho (sPGA) tau qhab nia rau daim tawv nqaij cov kab mob ua kom tiav clearance los yog yuav luag tiav clearance (sPGA). 0/1), piv nrog Otezla, feem ntau ntawm cov neeg mob tau mus txog PASI75 thiab sPGA 0/1 ntawm lub lim tiam 24 thiab khaws cia kom txog rau lub lim tiam 52. Hauv txoj kev tshawb no, deucravacitinib muaj kev nyab xeeb thiab ua tau zoo.